Developing autologous iPSC-derived cell replacement therapies for Parkinson’s disease and other CNS disorders
La Jolla, CA
Aspen Neuroscience is a clinical-stage regenerative medicine biotechnology company developing autologous induced pluripotent stem cell (iPSC)-derived therapies, beginning with Parkinson’s disease (PD). Our lead investigational therapy, sasineprocel (ANPD001), is designed to replace lost dopaminergic neurons and reconstruct the underlying neural circuitry to restore function and potentially slow disease progression—without the need for immunosuppression. At Aspen, our team is passionate about bringing our world class science and manufacturing to patients. We aim to transform the lives of people living with PD with our personalized regenerative therapies that offer real hope where none existed before.
On-site · Quinte West
Lead field-based clinical and technical support for neurosurgical Parkinson's cell therapy studies, ensuring site readiness and procedural execution. Translate field insights into scalable standards and operational strategies to improve surgical delivery across the clinical network.
